Application Note: Pharmacological Characterization of the Antibody Drug Conjugate, Kadcyla®, Using Live-Cell Analysis
Authors: Nicola Bevan, Kirsty McBain, Daryl Cole and Tim Dale | Last Updated: March 20, 2022
Overview
Antibody therapeutic developments have led to the discovery of new treatments for multiple diseases. In the cancer therapy field, the development of antibody drug conjugate (ADC) complexes are especially promising. ADCs exploit the specificity of monoclonal antibodies (mAbs) to achieve targeted cell death by delivering a cytotoxic drug directly to tumor cells expressing a characteristic marker or antigen.
There are numerous clinically relevant ADCs used to treat breast, leukaemia, multiple myeloma, and lymphoma cancers. Here, we explore Kadcyla®️, which is used against some forms of breast cancer. It is a combination ADC of Trastuzumab (Herceptin®️)—an antibody targeting the Human Epidermal Growth Factor Receptor 2 (HER2)—and emtansine (DM1)—a cytotoxic agent.
This Application Note exemplifies how the various biological activities of Kadcyla®️ can be characterized using the Incucyte®️ Live-Cell Analysis System in combination with multiple functional assessments.
- Document type: Application Note
- Page count: 8
- Read time: 16 minutes
Key Takeaways
- Comprehensive ADC characterization
- Enhanced visualization and quantification of Kadcyla®️’s effects
- Synergistic analytical approach for use in the development and research for future ADC therapeutics
Figure 1: Kadcyla® Molecule
